spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Myoglobin 

 HSMN NewsFeed - 20 Aug 2025
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
Devices FDA
 HSMN NewsFeed - 14 Apr 2025
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
Devices Personnel
 HSMN NewsFeed - 2 Nov 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Devices
 HSMN NewsFeed - 1 Jun 2022
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Devices Distribution
 HSMN NewsFeed - 2 May 2022
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
Devices Group Purchasing
 HSMN NewsFeed - 20 Dec 2021
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Devices
 HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA
 HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA
 HSMN NewsFeed - 11 Jan 2021
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
Devices Personnel
 HSMN NewsFeed - 31 Jul 2020
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
Devices
 HSMN NewsFeed - 28 Jul 2020
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
Devices
 HSMN NewsFeed - 24 Jun 2020
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
Devices Product Launch
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 4 May 2020
CytoSorbents Promotes Vincent J. Capponi to President
Devices Personnel
 HSMN NewsFeed - 31 Mar 2020
CytoSorb(R) Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
Devices Regulatory
 HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 11 Jan 2016
Industry Veteran Sherry Korczynski Joins Eagle Pharmaceuticals as Senior Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Jul 2013
FDA Grants Diazyme 510(k) Clearance to Market Its Myoglobin Assay for Clinical Chemistry Analyzers
Diagnostics Cardiology FDA
 HSMN NewsFeed - 31 May 2012
New Data Showed LIVALO(R) (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2008
Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests
Diagnostics Cardiology
 HSMN NewsFeed - 24 Jul 2008
Inverness Medical Innovations Extends Cardiology Products Distribution Agreement with Thermo Fisher Scientific
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2007
bioMerieux Launches VIDAS(R) NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure
Diagnostics Cardiology Regulatory
 HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Jun 2007
Response Biomedical Receives Approval to Market NT-proBNP Congestive Heart Failure Marker Test in Canada
Diagnostics Cardiology Regulatory
 HSMN NewsFeed - 18 May 2007
FDA Approves Astrazeneca's Once-Daily Seroquel XR(TM) Extended-Release Tablets for the Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 28 Sep 2006
Dade Behring Launches CardioPhase(R) hsCRP Test for Use on Its Stratus(R) CS Acute Care(TM) Diagnostic System
Diagnostics Cardiology
 HSMN NewsFeed - 24 Jul 2006
Response Biomedical Completes US Distribution Network For RAMP Cardiovascular Products
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 31 additional stories matching:
Myoglobin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!